Statements (28)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:monoclonal_antibody
|
| gptkbp:administeredBy |
subcutaneous injection
|
| gptkbp:approvalYear |
2018
|
| gptkbp:approvedBy |
gptkb:FDA
gptkb:EMA |
| gptkbp:ATCCode |
L04AC15
|
| gptkbp:brand |
gptkb:Ilumya
Ilumetri |
| gptkbp:CASNumber |
1049871-84-6
|
| gptkbp:developedBy |
gptkb:Sun_Pharma
|
| gptkbp:drugClass |
immunosuppressant
|
| https://www.w3.org/2000/01/rdf-schema#label |
tildrakizumab
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:macromoleculeType |
gptkb:IgG1_kappa
|
| gptkbp:mechanismOfAction |
inhibits IL-23p19 subunit
|
| gptkbp:monitors |
gptkb:physician
|
| gptkbp:notRecommendedFor |
children under 18
|
| gptkbp:pregnancyCategory |
not assigned (US)
|
| gptkbp:prescribes |
adults
|
| gptkbp:routeOfAdministration |
subcutaneous
|
| gptkbp:sideEffect |
diarrhea
injection site reaction upper respiratory tract infection |
| gptkbp:target |
gptkb:interleukin-23
|
| gptkbp:UNII |
Q1J0XQ4B2D
|
| gptkbp:usedFor |
plaque psoriasis
|
| gptkbp:bfsParent |
gptkb:Ilumya
|
| gptkbp:bfsLayer |
7
|